A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer

J. L. Chitty, M. Yam, L. Perryman, A. L. Parker, J. N. Skhinas, Y. F. I. Setargew, E. T. Y. Mok, E. Tran, R. D. Grant, S. L. Latham, B. A. Pereira, S. C. Ritchie, K. J. Murphy, M. Trpceski, A. D. Findlay, P. Melenec, E. C. Filipe, A. Nadalini, S. Velayuthar, G. MajorK. Wyllie, M. Papanicolaou, S. Ratnaseelan, P. A. Phillips, G. Sharbeen, J. Youkhana, A. Russo, A. Blackwell, J. F. Hastings, M. C. Lucas, C. R. Chambers, D. A. Reed, J. Stoehr, C. Vennin, R. Pidsley, A. Zaratzian, A. M. Da Silva, M. Tayao, B. Charlton, D. Herrmann, M. Nobis, S .J. Clark, A. V. Biankin, A. L. Johns, D. R. Croucher, A. Nagrial, A.J. Gill, S. M. Grimmond, L. A. Chantrill, A. Chou, T. Dwarte, X. L. Metcalf, G. Jeong, L. Kenyon, N. Waddell, J. V. Pearson, A.- M. Patch, K. Nones, F. Newell, P. Mukhopadhyay, V. Addala, S. Kazakoff, O. Holmes, C. Leonard, S. Wood, O. Hofmann, J. S. Samra, N. Pavlakis, J. Arena, H. A. High, R. Asghari, Neil D. Merrett, A. Das, P. H. Cosman, Kasim Ismail, A. Stoita, D. Williams, A. Spigellman, D. McLeo, J. Kirk, J. G. Kench, P. Grimison, C. Sandroussi, A. Goodwin, R. S. Mead, K. Tucker, L. Andrews, M. Texler, C. Forrest, M. Ballal, D. Fletcher, M. Beilin, K. Feeney, K. Epari, S. Mukhedkar, N. Zeps, N. Q. Nguyen, A. R. Ruszkiewicz, C. Worthley, J. Chen, M. E. Brooke-Smith, V. Papangelis, A. D. Clouston, A. P. Barbour, T. J. O’Rourke, J. W. Fawcett, K. Slater, M. Hatzifotis, P. Hodgkinson, M. Nikfarjam, J. R. Eshleman, R. H. Hruban, C. L. Wolfgang, A. Scarpa, R. T. Lawlor, V. Corbo, C. Bassi, N. B. Jamieson, D. K. Chang, S. B. Dreyer, L. Abdulkhalek, T. Schmitz, V. Lee, K. P. Stewart, M. Arshi, A. M. Steinmann, M. Pajic, P. Timpson, W. Jarolimek, T. R. Cox

Research output: Contribution to journalArticlepeer-review

Abstract

The lysyl oxidase family represents a promising target in stromal targeting of solid tumors due to the importance of this family in crosslinking and stabilizing fibrillar collagens and its known role in tumor desmoplasia. Using small-molecule drug-design approaches, we generated and validated PXS-5505, a first-in-class highly selective and potent pan-lysyl oxidase inhibitor. We demonstrate in vitro and in vivo that pan-lysyl oxidase inhibition decreases chemotherapy-induced pancreatic tumor desmoplasia and stiffness, reduces cancer cell invasion and metastasis, improves tumor perfusion and enhances the efficacy of chemotherapy in the autochthonous genetically engineered KPC model, while also demonstrating antifibrotic effects in human patient-derived xenograft models of pancreatic cancer. PXS-5505 is orally bioavailable, safe and effective at inhibiting lysyl oxidase activity in tissues. Our findings present the rationale for progression of a pan-lysyl oxidase inhibitor aimed at eliciting a reduction in stromal matrix to potentiate chemotherapy in pancreatic ductal adenocarcinoma.
Original languageEnglish
Pages (from-to)1326-1344
Number of pages19
JournalNature Cancer
Volume4
Issue number9
DOIs
Publication statusPublished - Sept 2023

Open Access - Access Right Statement

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Fingerprint

Dive into the research topics of 'A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer'. Together they form a unique fingerprint.

Cite this